贝康医疗-B(02170)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02170 贝康医疗-B

已收盘 09-04 15:58:45

1.375

+0.000

0.00%

最高1.400	最低1.290	成交量70.20万
今开1.295	昨收1.375	日振幅8.00%
总市值3.76亿	流通市值1.14亿	总股本2.74亿
成交额92.13万	换手率0.85%	流通股本8,271万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02170","market":"HK","secType":"STK","nameCN":"贝康医疗-B","latestPrice":1.375,"timestamp":1788508725830,"preClose":1.375,"halted":0,"volume":702000,"delay":0,"changeRate":0,"floatShares":82713835,"shares":273526000,"eps":-0.9550399819336626,"marketStatus":"已收盘","change":0,"latestTime":"09-04 15:58:45","open":1.295,"high":1.4,"low":1.29,"amount":921342,"amplitude":0.08,"askPrice":1.4,"askSize":11000,"bidPrice":1.36,"bidSize":14500,"shortable":0,"etf":0,"ttmEps":-0.7423923059985885,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1788744600000},"marketStatusCode":5,"adr":0,"listingDate":1612713600000,"exchange":"SEHK","adjPreClose":1.375,"openAndCloseTimeList":[[1788485400000,1788494400000],[1788498000000,1788508800000]],"volumeRatio":36,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02170","defaultTab":"news","newsList":[{"id":"1162628991","title":"贝康医疗8月股份变动月报：股本维持不变","url":"https://stock-news.laohu8.com/highlight/detail?id=1162628991","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1162628991?lang=zh_cn&edition=full","pubTime":"2026-09-03 17:35","pubTimestamp":1788428159,"startTime":"0","endTime":"0","summary":"苏州贝康医疗股份有限公司于2026年9月3日发布了截至2026年8月31日的证券变动月报表。公告显示，报告期内公司整体股本结构无变化，具体情况如下：。截至2026年8月31日，公司法定/注册股本总额为人民币273,526,000元，较上月保持不变。公司表示在此期间及此前并未回购公司任何上市证券，并将持续遵守香港联交所《上市规则》及相关法律法规。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"a3893e2538b44a4c9453f52433cb6ed2","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02170"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662910850","title":"贝康医疗-B(02170)发布中期业绩 净亏损7204.8万元 同比收窄40.7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662910850","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662910850?lang=zh_cn&edition=full","pubTime":"2026-08-28 22:53","pubTimestamp":1787928794,"startTime":"0","endTime":"0","summary":"智通财经APP讯，贝康医疗-B(02170)发布截至2026年6月30日止6个月中期业绩，集团收入人民币1.29亿元，同比增长27.05%;净亏损7204.8万元，同比收窄40.7%;每股亏损0.26元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1488618.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","BK1222","BK1597","02170"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1154397333","title":"贝康医疗-B2026年上半年营收1.29亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=1154397333","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1154397333?lang=zh_cn&edition=full","pubTime":"2026-08-28 21:37","pubTimestamp":1787924247,"startTime":"0","endTime":"0","summary":"截至2026年6月30日止六个月，贝康医疗-B实现营收约1.29亿元，同比增加27.0%。本期毛利约0.69亿元，同比提升30.3%。毛利率从上年同期的52.5%上升至53.8%，主要来自高毛利产品占比上升。销售及分销开支约0.49亿元，同比减少7.2%。行政开支约0.49亿元，同比下降21.8%。研发投入约0.33亿元，同比减少42.4%。在中国市场方面，收入同比增长35.1%。海外市场双轮驱动下，亚太地区收入同比增长88.1%，其中韩国、日本、泰国及越南等地需求强劲。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"贝康医疗-B2026年上半年营收1.29亿元","news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02170"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1116875293","title":"贝康医疗-B（02170）将于8月28日召开董事会审议2026年中期业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=1116875293","media":"公告速递","labels":["conferences","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1116875293?lang=zh_cn&edition=full","pubTime":"2026-08-18 18:10","pubTimestamp":1787047833,"startTime":"0","endTime":"0","summary":"贝康医疗-B（02170）8月18日公告，公司董事会计划于2026年8月28日（星期五）举行会议，主要议程包括：\n\\n\n\\n1. 审议并批准公司及其附属公司截至2026年6月30日止六个月的中期业绩及其发布；\n\\n\n\\n2. 讨论并考虑建议派发中期股息（如有）。\n\\n\n\\n公告显示，董事会成员包括执行董事梁波博士、孔令印先生及姜雋超女士；非执行董事赵业先生及王伟鹏先生；独立非执行董事康熙雄博士、林兆荣先生及杨树标博士。\n\\n\n\\n公司董事长兼总经理梁波博士已签署本次董事会会议通告。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02170"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659585177","title":"贝康医疗-B预计上半年亏损收窄39.5%至43.2%","url":"https://stock-news.laohu8.com/highlight/detail?id=2659585177","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659585177?lang=zh_cn&edition=full","pubTime":"2026-08-16 21:44","pubTimestamp":1786887840,"startTime":"0","endTime":"0","summary":"8月16日，贝康医疗-B（02170）发布公告，预计截至2026年6月30日止六个月的收入约为1.26亿元至1.31亿元，较2025年同期的1.01亿元同比增长约24.0%至29.0%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608163842547457.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608163842547457.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["02170","BK1222","BK1597","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659726661","title":"贝康医疗-B(02170)预期中期收入约1.26亿元至1.31亿元 同比增长约24.0%至29.0%","url":"https://stock-news.laohu8.com/highlight/detail?id=2659726661","media":"中金财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659726661?lang=zh_cn&edition=full","pubTime":"2026-08-16 19:27","pubTimestamp":1786879622,"startTime":"0","endTime":"0","summary":"智通财经APP讯，贝康医疗-B 发布公告，收入增长：截至2026年6月30日止6个月，预计取得收入约人民币1.26亿元至人民币1.31亿元，较截至2025年6月30日止6个月的人民币1.01亿元同比增长约24.0%至29.0%。　　亏损收窄：截至2026年6月30日止6个月，预计取得归属权益股东亏损约人民币6900万元至人民币7350万元，同比收窄约39.5%至43.2%;取得负税息折旧及摊销前利润约人民币4440万元至人民币4900万元，同比收窄约46.9%至51.9%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260816/32336343.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK1222","BK1597","BK1574","02170"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1126637206","title":"贝康医疗-B预计上半年收入增逾两成 亏损同比收窄约四成","url":"https://stock-news.laohu8.com/highlight/detail?id=1126637206","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1126637206?lang=zh_cn&edition=full","pubTime":"2026-08-16 18:51","pubTimestamp":1786877467,"startTime":"0","endTime":"0","summary":"香港联合交易所主板上市公司贝康医疗-B8月16日晚间发布盈利预告称，截至2026年6月30日止六个月，公司预计实现收入约1.26亿元至1.31亿元，较去年同期的1.013亿元增长约24.0%至29.0%。同期，公司预计录得归属权益股东净亏损约69.0百万元至73.5百万元，同比收窄约39.5%至43.2%；负EBITDA亏损约44.4百万元至49.0百万元，同比收窄约46.9%至51.9%。公司表示，相关数据基于未经审计的管理账目初步评估，最终业绩将于2026年8月底发布的中期业绩公告中披露。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02170"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1191733366","title":"贝康医疗-B 7月股份变动月报表：股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1191733366","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1191733366?lang=zh_cn&edition=full","pubTime":"2026-08-03 17:33","pubTimestamp":1785749623,"startTime":"0","endTime":"0","summary":"苏州贝康医疗股份有限公司于2026年8月3日发布了截至2026年7月31日的股份变动月报表。公告显示，公司注册股本和已发行股份在本报告期内均未发生变动，股本保持稳定。根据公告，贝康医疗-B当前拥有普通股H股82,713,835股、内资股183,181,817股、未上市外资股7,630,348股，所有股份面值均为每股人民币1元。报告期内，各类别股份数量没有增加或减少，发行总股本仍合计273,526,000元人民币。本次公告由执行董事梁波签署。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02170"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1171930139","title":"贝康医疗-B2026年6月股份变动月报表发布，股本维持不变","url":"https://stock-news.laohu8.com/highlight/detail?id=1171930139","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1171930139?lang=zh_cn&edition=full","pubTime":"2026-07-07 17:13","pubTimestamp":1783415586,"startTime":"0","endTime":"0","summary":"2026年7月7日，苏州贝康医疗股份有限公司（股票代码：02170，股票名称：贝康医疗-B）发布2026年6月股份变动月报表。公告显示，截至2026年6月30日，公司法定/注册股本合计人民币273,526,000元，包含H股82,713,835股、内资股183,181,817股和未上市外资股7,630,348股，各类股份数均保持不变。\n报告期内，公司无新增发行、购回、注销或库藏股活动，股本结构维持稳定；同时无股份期权或股权激励计划的变动。公司声明已遵守香港联交所《上市规则》及相关法律规定，并确认自2026年1月1日起并无回购任何上市证券。\n本次月报由执行董事梁波签署。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02170"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647328063","title":"格隆汇2026中期策略峰会“All in 硅基新纪元”暨“金格奖”——卓越公司榜单全部揭晓！","url":"https://stock-news.laohu8.com/highlight/detail?id=2647328063","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2647328063?lang=zh_cn&edition=full","pubTime":"2026-06-29 13:08","pubTimestamp":1782709733,"startTime":"0","endTime":"0","summary":"本次评选共设有14个奖项","market":"sg","thumbnail":"https://img3.gelonghui.com/9dec8-575c2ec7-abca-4b10-b7d8-3bd3f2cd0682.jpg?guru_height=741&guru_width=1140&guru_size=148310","type":0,"news_type":0,"thumbnails":["https://img3.gelonghui.com/9dec8-575c2ec7-abca-4b10-b7d8-3bd3f2cd0682.jpg?guru_height=741&guru_width=1140&guru_size=148310"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/5373783","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["06963","000338","02170","02553","000951","02273","00780","01384","02661","00917","09992","07688","02687","09878","09678","06668","002779","02643","02555","03692","01768","002352","02121","002714","01833","01497","01021","002594","01519","09959","02408","01024","02590","002600","02279","02718","06979","03690","01952","000039","02729","00600","300760","300364","01951","09880","001248","02526","02105","02511"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1149568964","title":"贝康医疗-B更新2026年5月股份变动月报表，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1149568964","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1149568964?lang=zh_cn&edition=full","pubTime":"2026-06-03 16:37","pubTimestamp":1780475822,"startTime":"0","endTime":"0","summary":"苏州贝康医疗股份有限公司于2026年6月3日发布了截至2026年5月31日的股份变动月报表。公告显示，公司本月底法定/注册股本总额维持在人民币273,526,000元，报告期内整体股本结构无新增发行、回购或注销情况。根据公告，贝康医疗-B目前已发行普通股合计273,526,000股，具体包含H股82,713,835股，内资股183,181,817股及未上市外资股7,630,348股，面值均为人民币1元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02170"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639867886","title":"贝康医疗-B(02170)：GEMS取卵液获国家药监局颁发三类医疗器械注册证","url":"https://stock-news.laohu8.com/highlight/detail?id=2639867886","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2639867886?lang=zh_cn&edition=full","pubTime":"2026-05-29 21:21","pubTimestamp":1780060885,"startTime":"0","endTime":"0","summary":"智通财经APP讯，贝康医疗-B 发布公告，本公司Gems系列的取卵液于近日获得国家药品监督管理局颁发的三类医疗器械注册证。取卵液是IVF诊疗第一道核心试剂，为后续受精、卵裂、囊胚发育提供前置保障。本次获批标志着Gems系列试剂逐步完成全品类闭环布局。目前取卵液、胚胎处理液、受精液、卵裂胚培养液、囊胚培养液、胚胎培养液六款产品已全部拿证，覆盖取卵、配子处理、受精、胚胎培养全诊疗链路。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1448041.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09996","BK1583","BK1597","02170","159883","BK1100","BK1574","BK1222"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1145491560","title":"苏州贝康医疗-B：获国家药监局三类医疗器械注册证，Gems取卵液获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=1145491560","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1145491560?lang=zh_cn&edition=full","pubTime":"2026-05-29 21:20","pubTimestamp":1780060824,"startTime":"0","endTime":"0","summary":"苏州贝康医疗-B宣布，其Gems取卵液产品已正式获得中国国家药品监督管理局颁发的第三类医疗器械注册证。该批准标志着公司辅助生殖领域产品线的重要拓展，为相关临床需求提供了新的解决方案。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","BK1597","BK1222","02170"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635789775","title":"贝康医疗-B(02170)：Gems卵裂胚培养液获国家药监局颁发三类医疗器械证","url":"https://stock-news.laohu8.com/highlight/detail?id=2635789775","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2635789775?lang=zh_cn&edition=full","pubTime":"2026-05-13 19:29","pubTimestamp":1778671793,"startTime":"0","endTime":"0","summary":"智通财经APP讯，贝康医疗-B 发布公告，公司自主研发的Gems卵裂胚培养液于近日成功获批国家三类医疗器械注册证。在此次获批之前，Gems卵裂胚培养液已分别取得欧洲合格认证、 美 国食品药品监督管理局认证及澳大利亚药品管理局认证。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1441354.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","159883","BK1100","09996","BK1222","BK1597","BK1583","02170"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1181129719","title":"贝康医疗-B 获得NMPA三类医疗器械注册证 其胚胎培养液产品获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=1181129719","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1181129719?lang=zh_cn&edition=full","pubTime":"2026-05-13 19:27","pubTimestamp":1778671638,"startTime":"0","endTime":"0","summary":"苏州贝康医疗股份有限公司近日宣布，其研发的Gems Cleavage胚胎培养液产品，已成功获得国家药品监督管理局颁发的三类医疗器械注册证。\n此次获批标志着该产品获准在中国市场正式上市销售，为公司辅助生殖产品线增添了重要的核心产品。三类医疗器械是监管级别最高的医疗器械，通常用于支持或维持生命，其注册审批过程严格且复杂。\n该胚胎培养液主要用于辅助生殖技术中的胚胎体外培养环节，是胚胎发育过程中的关键耗材。此次获批有望进一步巩固贝康医疗在辅助生殖领域的市场地位，并为其未来业绩增长提供新的动力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","02170","BK1222","BK1597"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634219560","title":"贝康医疗-B(02170)拟实施H股全流通计划","url":"https://stock-news.laohu8.com/highlight/detail?id=2634219560","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2634219560?lang=zh_cn&edition=full","pubTime":"2026-05-12 20:09","pubTimestamp":1778587773,"startTime":"0","endTime":"0","summary":"智通财经APP讯，贝康医疗-B(02170)公布，董事会已审议及批准建议实施H股全流通，以转换合共约1.91亿股公司未上市股份为公司H股。待取得所有相关批准及╱或备案(包括中国证监会的备案通知及联交所的批准)并符合所有适用法律、法规及规则后，该等未上市股份将转换为H股，且公司将申请批准该等H股于联交所主板上市及买卖。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1440856.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1597","BK1222","BK1574","02170"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1125751121","title":"贝康医疗-B发布2026年4月股份变动月报，股本保持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1125751121","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1125751121?lang=zh_cn&edition=full","pubTime":"2026-05-06 16:49","pubTimestamp":1778057346,"startTime":"0","endTime":"0","summary":"苏州贝康医疗股份有限公司于2026年5月6日发布截至2026年4月30日的证券变动月报表。本月公司注册股本与已发行股份总数均未发生变化。报告显示，截至4月末，公司股本总额为人民币273,526,000元，每股面值人民币1元。公司明确指出，自2026年1月1日起，未回购任何上市证券。公司表示将继续严格遵守香港联交所《上市规则》及其他相关法律法规的规定，并将按时披露后续的股份变动信息。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02170"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1163529632","title":"贝康医疗-B获PGT-M试剂盒三类医疗器械注册证","url":"https://stock-news.laohu8.com/highlight/detail?id=1163529632","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1163529632?lang=zh_cn&edition=full","pubTime":"2026-04-29 20:11","pubTimestamp":1777464677,"startTime":"0","endTime":"0","summary":"苏州贝康医疗股份有限公司宣布，其PGT-M试剂盒已成功获得国家药品监督管理局颁发的三类医疗器械注册证书。这一重要资质的取得，标志着该产品获准在中国市场正式上市销售与应用。\n三类医疗器械注册证是医疗器械监管体系中的最高级别认证，通常适用于具有较高风险、需要采取特别措施严格控制管理以保证其安全有效的医疗器械。此次获批的PGT-M试剂盒将主要用于胚胎植入前遗传学检测，有助于提升辅助生殖领域的精准诊断水平。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02170","BK1574","BK1222","BK1597"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631251557","title":"贝康医疗-B(02170)：PGT-M试剂盒获国家药监局颁发三类医疗器械证","url":"https://stock-news.laohu8.com/highlight/detail?id=2631251557","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2631251557?lang=zh_cn&edition=full","pubTime":"2026-04-29 19:40","pubTimestamp":1777462801,"startTime":"0","endTime":"0","summary":"本次获批的PGT-M试剂盒是国内首个针对地中海贫血家系遗传阻断的PGT-M产品，填补了我国单基因病胚胎植入前遗传学检测领域的国产空白。随着PGT-M试剂盒获批上市，集团的产品线进一步丰富，将有效带动遗传实验室业务收入增长，有望成为公司未来业绩增长的重要驱动力，并进一步巩固集团在中国三代试管婴儿基因检测试剂盒市场的领导地位。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1436459.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09996","BK1583","BK1597","02170","159883","09997","BK1100","BK1574","BK1222"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1128359768","title":"贝康医疗-B（02170）2025年度业绩：收入2.33亿元 毛利率升至53%，年内亏损小幅收窄","url":"https://stock-news.laohu8.com/highlight/detail?id=1128359768","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1128359768?lang=zh_cn&edition=full","pubTime":"2026-04-22 16:54","pubTimestamp":1776848062,"startTime":"0","endTime":"0","summary":"贝康医疗-B公布截至2025年12月31日止年度的经营及财务表现。财务数据显示，公司全年收入为2.33亿元人民币，较2024年的2.99亿元同比下降22.0%；毛利达1.24亿元，较上年度1.36亿元下降9.3%，同时毛利率由45.5%上升至53.0%。年内亏损为2.23亿元，较2024年的2.37亿元有所收窄，亏损幅度减少约5.8%。展望后续阶段，贝康医疗-B将继续深化“IVD至IVF”平台布局，聚焦生殖诊断和辅助生殖器械的研发与市场推广，并通过海外合作与本地化生产提升供应链效能。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"贝康医疗-B（02170）2025年度业绩：收入2.33亿元 毛利率升至53%，年内亏损小幅收窄","news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02170"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"stockEarnings":[{"period":"1week","weight":0.0185},{"period":"1month","weight":-0.0317},{"period":"3month","weight":-0.0179},{"period":"6month","weight":-0.2686},{"period":"1year","weight":-0.598},{"period":"ytd","weight":-0.2608}],"compareEarnings":[{"period":"1week","weight":-0.0138},{"period":"1month","weight":-0.0247},{"period":"3month","weight":0.0101},{"period":"6month","weight":-0.0211},{"period":"1year","weight":-0.0051},{"period":"ytd","weight":-0.0163}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"苏州贝康医疗股份有限公司（原名：江苏双螺旋生物科技有限公司）是一家主要提供辅助生殖基因检测解决方案的中国投资控股公司。该公司提供基因检测解决方案及销售基因检测设备及仪器。基因检测解决方案包括销售检测试剂盒及提供检测服务。该公司主要产品包括PGT-A试剂盒。该公司主要于国内市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":0.002951},{"month":2,"riseRate":0.6,"avgChangeRate":0.105265},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.100603},{"month":4,"riseRate":0.5,"avgChangeRate":0.007862},{"month":5,"riseRate":0.166667,"avgChangeRate":-0.103247},{"month":6,"riseRate":0.166667,"avgChangeRate":-0.024761},{"month":7,"riseRate":0.333333,"avgChangeRate":-0.041153},{"month":8,"riseRate":0.333333,"avgChangeRate":-0.045314},{"month":9,"riseRate":0.5,"avgChangeRate":-0.006377},{"month":10,"riseRate":0.4,"avgChangeRate":0.015037},{"month":11,"riseRate":0.2,"avgChangeRate":-0.017242},{"month":12,"riseRate":0.2,"avgChangeRate":-0.11073}],"exchange":"SEHK","name":"贝康医疗-B","nameEN":"BASECARE-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"贝康医疗-B(02170)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供贝康医疗-B(02170)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"贝康医疗-B,02170,贝康医疗-B股票,贝康医疗-B股票老虎,贝康医疗-B股票老虎国际,贝康医疗-B行情,贝康医疗-B股票行情,贝康医疗-B股价,贝康医疗-B股市,贝康医疗-B股票价格,贝康医疗-B股票交易,贝康医疗-B股票购买,贝康医疗-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"贝康医疗-B(02170)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供贝康医疗-B(02170)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}